<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659578</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO-1043</org_study_id>
    <nct_id>NCT03659578</nct_id>
  </id_info>
  <brief_title>Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Study of Thymopeptide a1 During Split-course Chemoradiotherapy to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II study is to determine the efficacy of Thymosin α1 on the frequency of acute
      pneumonia in non-small cell lung cancer with bulky tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II study is to determine the efficacy of Thymosin α1 on the frequency of acute
      pneumonia in non-small cell lung cancer with bulky tumor.

      All patients received four cycles of weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡)(DP),
      each of 1 day's duration, combined with split-course thoracic radiotherapy of 51 Gy/17
      fractions and 15 Gy/5 fractions administered in the first and second courses, respectively,
      with one-month break.In the consolidation arm, patients were further treated with
      subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation
      to 2 months after the end of radiation. Toxicities will be graded according to CTCAE v. 4.0.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of acute pneumonia</measure>
    <time_frame>1-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pulmonary ventilation and diffusion capacity decline degree(SOMA)</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphocyte count</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>grade of pulmonary fibrosis(SOMA)</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>grade of radiation-induced lung injury(NCI-CTC4.0)</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Thymosin α1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent chemotherapy</intervention_name>
    <description>Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.</description>
    <arm_group_label>Thymosin α1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>split-course radiotherapy</intervention_name>
    <description>split-course chest radiation at 51Gy/17f and 15Gy/5f</description>
    <arm_group_label>Thymosin α1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thymosin alpha 1</intervention_name>
    <description>subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.</description>
    <arm_group_label>Thymosin α1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic confirmation of NSCLC.

          -  Patients have measurable or evaluable lesions based on the Response Evaluation
             Criteria in Solid Tumors (RECIST) criteria.

               -  Unresectable phase IIIA(N2) and IIIB lung cancer confirmed by PET/CT, CT or MRI.

               -  Whole lung V20&gt;=35% when giving 60Gy which is the minimum dose of radical
                  irradiation.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  Previously treated with chemotherapy or treatment-naive

          -  No previous chest radiotherapy, immunotherapy or biotherapy

          -  Hemoglobin≥10 mg/dL, platelet≥100000/μL,absolute neutrophil count ≥1500/μL

          -  Serum creatinine ≤1.25 times the upper normal limit(UNL), or creatinine clearance≥60
             ml/min

          -  Bilirubin ≤1.5 times UNL, AST（SGOT）≤2.5 times UNL ,ALT（SGPT）≤2.5 times UNL,alkaline
             phosphatase ≤5 times UNL

          -  FEV1 &gt;0.8 L

          -  CB6 within normal limits

          -  patients and their family signed the informed consents

        Exclusion Criteria:

          -  Previous or recent another malignancy, except nonmelanoma skin cancer or cervical
             cancer in situ

          -  Contraindication for chemotherapy

          -  Malignant pleural or pericardial effusion.

          -  Women in pregnancy, lactation period, or no pregnancy test 14 days before the first
             dose

          -  Women who has the probability of pregnancy without contraception

          -  Tendency of hemorrhage

          -  In other clinical trials within 30 days

          -  Addicted in drugs or alcohol, AIDS patients

          -  Uncontrollable seizure or psychotic patients without self-control ability

          -  Severe allergy or idiosyncrasy

          -  Not suitable for this study judged by researchers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bo Qiu, Attending</last_name>
    <phone>+86-020-87343031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui liu, Professor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Qiu, Attending</last_name>
      <phone>+86-020-87343031</phone>
      <email>qiubo@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hui Liu, Professor</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </reference>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.</citation>
    <PMID>28055103</PMID>
  </reference>
  <reference>
    <citation>Méry B, Guy JB, Swalduz A, Vallard A, Guibert C, Almokhles H, Ben Mrad M, Rivoirard R, Falk AT, Fournel P, Magné N. The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience. Crit Rev Oncol Hematol. 2015 Nov;96(2):319-27. doi: 10.1016/j.critrevonc.2015.05.020. Epub 2015 Jun 7. Review.</citation>
    <PMID>26095618</PMID>
  </reference>
  <reference>
    <citation>Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999 Sep;17(9):2692-9.</citation>
    <PMID>10561343</PMID>
  </reference>
  <reference>
    <citation>Wang T, Nelson RA, Bogardus A, Grannis FW Jr. Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer. 2010 Mar 15;116(6):1518-25. doi: 10.1002/cncr.24871.</citation>
    <PMID>20108308</PMID>
  </reference>
  <reference>
    <citation>Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. doi: 10.1093/jnci/djr325. Epub 2011 Sep 8. Erratum in: J Natl Cancer Inst. 2012 Jan 4;104(1):79.</citation>
    <PMID>21903745</PMID>
  </reference>
  <reference>
    <citation>Fournel P, Robinet G, Thomas P, Souquet PJ, Léna H, Vergnenégre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daurés JP, Mornex F, Pérol M; Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol. 2005 Sep 1;23(25):5910-7. Epub 2005 Aug 8.</citation>
    <PMID>16087956</PMID>
  </reference>
  <reference>
    <citation>Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010 May 1;28(13):2181-90. doi: 10.1200/JCO.2009.26.2543. Epub 2010 Mar 29. Review.</citation>
    <PMID>20351327</PMID>
  </reference>
  <reference>
    <citation>Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV, Timmerman RD, Martel MK, Jackson A. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S70-6. doi: 10.1016/j.ijrobp.2009.06.091. Review.</citation>
    <PMID>20171521</PMID>
  </reference>
  <reference>
    <citation>Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun;6(6):1079-86. doi: 10.1097/JTO.0b013e3182199a7c.</citation>
    <PMID>21532501</PMID>
  </reference>
  <reference>
    <citation>Spoelstra FO, Pantarotto JR, van Sörnsen de Koste JR, Slotman BJ, Senan S. Role of adaptive radiotherapy during concomitant chemoradiotherapy for lung cancer: analysis of data from a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1092-7. doi: 10.1016/j.ijrobp.2008.12.027. Epub 2009 Mar 26.</citation>
    <PMID>19327915</PMID>
  </reference>
  <reference>
    <citation>Dang J, Li G, Ma L, Diao R, Zang S, Han C, Zhang S, Yao L. Predictors of grade ≥ 2 and grade ≥ 3 radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with three-dimensional conformal radiotherapy. Acta Oncol. 2013 Aug;52(6):1175-80. doi: 10.3109/0284186X.2012.747696. Epub 2012 Dec 3.</citation>
    <PMID>23198719</PMID>
  </reference>
  <reference>
    <citation>Ji K, Zhao LJ, Liu WS, Liu ZY, Yuan ZY, Pang QS, Wang J, Wang P. Simultaneous integrated boost intensity-modulated radiotherapy for treatment of locally advanced non-small-cell lung cancer: a retrospective clinical study. Br J Radiol. 2014 Mar;87(1035):20130562. doi: 10.1259/bjr.20130562. Epub 2014 Jan 27.</citation>
    <PMID>24588668</PMID>
  </reference>
  <reference>
    <citation>McDonald S, Rubin P, Phillips TL, Marks LB. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1187-203. Review.</citation>
    <PMID>7713782</PMID>
  </reference>
  <reference>
    <citation>Barthelemy-Brichant N, Bosquée L, Cataldo D, Corhay JL, Gustin M, Seidel L, Thiry A, Ghaye B, Nizet M, Albert A, Deneufbourg JM, Bartsch P, Nusgens B. Increased IL-6 and TGF-beta1 concentrations in bronchoalveolar lavage fluid associated with thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):758-67.</citation>
    <PMID>14967431</PMID>
  </reference>
  <reference>
    <citation>Trott KR, Herrmann T, Kasper M. Target cells in radiation pneumopathy. Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):463-9.</citation>
    <PMID>14751516</PMID>
  </reference>
  <reference>
    <citation>Rasmussen L, Arvin A. Chemotherapy-induced immunosuppression. Environ Health Perspect. 1982 Feb;43:21-5. Review.</citation>
    <PMID>7037385</PMID>
  </reference>
  <reference>
    <citation>Brambilla C, Romand P, Vanderkerckhove C, Moro D. [Respiratory infection and bronchial cancer]. Rev Mal Respir. 1992;9 Suppl 1:R49-52. French.</citation>
    <PMID>1317051</PMID>
  </reference>
  <reference>
    <citation>Klastersky J. [The infectious complications of bronchial cancer]. Rev Mal Respir. 1998 Sep;15(4):451-9. Review. French.</citation>
    <PMID>9805755</PMID>
  </reference>
  <reference>
    <citation>Zhuang H, Yuan Z, Chang JY, Wang J, Pang Q, Zhao L, Wang P. Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy. J Thorac Oncol. 2014 Jun;9(6):882-5. doi: 10.1097/JTO.0000000000000126.</citation>
    <PMID>24828665</PMID>
  </reference>
  <reference>
    <citation>Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, Chen J, Ou-Yang B, Chen M, Li Y, Wu X, Gu B, Chen L, Zou Z, Qiang X, Chen Y, Lin A, Zhang G, Guan X. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013 Jan 17;17(1):R8. doi: 10.1186/cc11932.</citation>
    <PMID>23327199</PMID>
  </reference>
  <reference>
    <citation>Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, Pitzurra L, Bellocchio S, Velardi A, Rasi G, Di Francesco P, Garaci E. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004 Jun 1;103(11):4232-9. Epub 2004 Feb 24.</citation>
    <PMID>14982877</PMID>
  </reference>
  <reference>
    <citation>Zheng BX, Cheng DY, Xu G, Fan LL, Yang Y, Yang W. [The prophylactic effect of thymosin alpha 1 on the acute exacerbation of chronic obstructive pulmonary disease]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 Jul;39(4):588-90. Chinese.</citation>
    <PMID>18798500</PMID>
  </reference>
  <reference>
    <citation>Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer. 2004 Oct;46(1):87-98.</citation>
    <PMID>15364136</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 2, 2018</study_first_submitted>
  <study_first_submitted_qc>September 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Split-course Chemoradiotherapy</keyword>
  <keyword>Thymosin a1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

